|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of gastric cancer显示文摘The authors focused on the current surgical treatment of resectable gastric cancer,and significance of periand post-operative chemo or chemoradiation.Gastric cancer is the 4thmost commonly diagnosed cancer and the second leading cause of cancer death worldwide.Surgery remains the only curative therapy,while perioperative and adjuvant chemotherapy,as well as chemoradiation,can improve outcome of resectable gastric cancer with extended lymph node dissection.More than half of radically resected gastric cancer patients relapse locally or with distant metastases,or receive the diagnosis of gastric cancer when tumor is disseminated;therefore,median survival rarely exceeds12 mo,and 5-years survival is less than 10%.Cisplatin and fluoropyrimidine-based chemotherapy,with addition of trastuzumab in human epidermal growth factor receptor 2 positive patients,is the widely used treatment in stageⅣpatients fit for chemotherapy.Recent evidence supports the use of second-line chemotherapy after progression in patients with good performance | Michele Orditura Gennaro Galizia Vincenzo Sforza Valentina Gambardella Alessio Fabozzi Maria Maddalena Laterza Francesca Andreozzi Jole Ventriglia Beatrice Savastano Andrea Mabilia Eva Lieto Fortunato Ciardiello Ferdinando De Vita | 2014 | World Journal of Gastroenterology2014，20，7： | 116 |
| 2 | Clinical management of advanced gastric cancer: The role of new molecular drugs显示文摘Gastric cancer is the fourth most common malignant neoplasm and the second leading cause of death for cancer in Western countries with more than 20000 new cases yearly diagnosed in the United States.Surgery represents the main approach for this disease but,notwithstanding the advances in surgical techniques,we observed a minimal improvement in terms of overall survival with a significant increasing of relapsing disease rates.Despite the development of new drugs has significantly improved the effectiveness of chemothera-py,the prognosis of patients with unresectable or metastatic gastric adenocarcinoma remains poor.Recently,several molecular target agents have been investigated;in particular,trastuzumab represents the first target molecule showing improvements in overall survival in human epithelial growth factor 2-positive gastric cancer patients.New molecules targeting vascular epithelial growth factor,mammalian target of rapamycin,and anti hepatocyte growth factor-c-Met pathway are also under investigation,with interesting results.Anyway,it seems necessary to select more accurately the population to treat with new agents by the identification of new biomarkers in order to optimize the results.In this paper we review the actual'scenario'of targeted treatments,also focusing on the new agents in development for gastric cancer and gastro-esophageal carcinoma,discussing their efficacy and potential applications in clinical practice. | Ferdinando De Vita Natale Di Martino Alessio Fabozzi Maria Maddalena Laterza Jole Ventriglia Beatrice Savastano Angelica Petrillo Valentina Gambardella Vincenzo Sforza Luigi Marano Annamaria Auricchio Gennaro Galizia Fortunato Ciardiello Michele Orditura | 2014 | World Journal of Gastroenterology2014，20，40： | 12 |
| 3 | Treatment of esophagogastric junction carcinoma:An unsolved debate显示文摘The incidence of esophagogastric junction adenocarcinoma(AEG) is increasing worldwide. Barrett's esophagus(BE) associated with dysplasia is the main risk factor for the development of cancer. Currently, screening programs to individuate and eradicate BE represent the best way to reduce AEG cancer. Several endoscopic approaches are here discussed. Surgicalstrategies for different types of AEG cancer are now fairly standardized, and multidisciplinary strategies u s i n g c h e m o t h e ra py o r c h e m o ra d i o t h e ra py m ay improve the outcome of these patients. Here we briefly discuss the keypoints, main topics, and critical issues, according to accumulating evidence and taking into account our own experience. | Michele Orditura Gennaro Galizia Eva Lieto Ferdinando De Vita Fortunato Ciardiello | 2015 | World Journal of Gastroenterology2015，21，15： | 10 |
| 4 | Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study显示文摘 | Gennaro Galizia Eva Lieto Ferdinando Vita Francesca Ferraraccio Anna Zamboli Andrea Mabilia Annamaria Auricchio Paolo Castellano Vincenzo Napolitano Michele Orditura | 2014 | International Journal of Colorectal Disease2014，，1： | 3 |
| 5 | Safety and efficacy of sorafenib in patients with advanced hepatocellularcarcinoma and Child-Pugh A or B cirrhosis显示文摘 | Alessandro Federico Michele Orditura Gaetano Cotticelli Ilario De Sio Marco Romano Antonietta Gravina Marcello Dallio Alessio Fabozzi Fortunato Ciardiello Carmela Loguercio Ferdinando De Vita | 2015 | Oncology Letters2015，，4： | 2 |
| 6 | Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis显示文摘 | Gennaro Galizia Eva Lieto Ferdinando De Vita Paolo Castellano Francesca Ferraraccio Anna Zamboli Andrea Mabilia Annamaria Auricchio Gabriele De Sena Lorenzo De Stefano Francesca Cardella Alfonso Barbarisi Michele Orditura | 2014 | Surgery2014，，： | 2 |
| 7 | Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery显示文摘 | Gennaro Galizia Eva Lieto Michele Orditura Paolo Castellano Anna La Mura Vincenzo Imperatore Margherita Pinto Anna Zamboli Ferdinando Vita Francesca Ferraraccio | 2007 | World Journal of Surgery2007，，7： | 2 |
| 8 | Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients 显示文摘 | De Vita F Orditura M Galizia G | 2000 | Chest2000，117，2： | 1 |
| 9 | Hypercoaguiable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C显示文摘 | De lucia D De Vita F Orditura M | 1997 | Tumor1997，83，6： | 1 |
| 10 | A phase Ⅱ study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid as first line treatment advanced or metastatic gastric cancer patients显示文摘 | De Vita F Orditura M Matano E | 2005 | Br J Cancer2005，92，9： | 1 |
| 11 | Elevated serum lev- els of interleukin-8 in advanced non-small cell lung cancer patients & relationship with prognosis显示文摘 | Orditura M Vita F Catalano G | 2002 | J Interferon Cy tokine Res2002，22，11： | 1 |
| 12 | Eepresssion of vascular endothelia lgrowth facter and epidermal drowth factor is an independent prognostic indicator of worse outcome in gastric cancer patients显示文摘 | FERRARACIO F ORDITURA M | 2008 | Ann Surg Oncol2008，15，1： | 1 |
| 13 | Epidermal growth fac-tor receptor(EGFR)expression is associated with a worseprognosis in gastric cancer patients undergoing curativesurgery显示文摘 | Galizia G Lieto E Orditura M | 2007 | World J Surg2007，31，： | 1 |
| 14 | Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery显示文摘 | Galizia G Lieto E Orditura M | 2007 | World J Surg2007，31，7： | 1 |
| 15 | Behaviour of interleukin-2 serum levels in advanced non-small cell lung cancer patients:relationship with response to therapy and survival 显示文摘 | Orditura M Romano C De Vita F | 2000 | Cancer Immunol Immunother2000，49，10： | 1 |
| 16 | Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients 显示文摘 | Lieto E Ferraraccio F Orditura M | 2008 | Ann Surg Oncol2008，15，1： | 1 |
| 17 | Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery显示文摘 | Galizia G Lieto E Orditura M Castellano P Mura A L Imperatore V | 2007 | World J Surg2007，31，： | 1 |
| 18 | A phase Ⅱ study of bi- weekly oxaliplatin plus ilffusional 5-fluorouracil and folin-icacid (FOLFOX-4) as first-line treatment of advanced gastriccancerpa- tients显示文摘 | De Vita F Orditura M Matano E | 2005 | Br J Cancer2005，92，： | 1 |
| 19 | Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery显示文摘 | Galizia G Orditura M liomauo C | | 0，，02： | 1 |
| 20 | Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery 显示文摘 | Galizia G Lieto E Orditura M | 2007 | World J Surg2007，31，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员